Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Colgate-Palmolive Company (NYSE: CL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings provide detailed information on Colgate-Palmolive’s Oral Care, Personal Care, Home Care and Pet Nutrition businesses, its financial performance and its capital structure.
Colgate-Palmolive’s 8-K filings illustrate how the company uses SEC reports to communicate material events. For example, an 8-K dated November 10, 2025 describes the execution of an underwriting agreement and the issuance of €600,000,000 of 3.250% Senior Notes due 2035 under an automatic shelf registration statement. Other 8-Ks furnish quarterly earnings press releases and explain multi-year productivity initiatives, such as the Strategic Growth and Productivity Program designed to support the company’s 2030 strategy by aligning its organizational structure, optimizing its global supply chain and streamlining overhead.
Filings also list Colgate-Palmolive’s securities registered under Section 12(b) of the Exchange Act, including its common stock (ticker CL) and various series of notes traded on the New York Stock Exchange. Through proxy statements and other periodic reports, investors can review topics such as segment reporting, non-GAAP financial measures like Base Business and organic sales growth, and risk factor disclosures.
On Stock Titan, these SEC documents are updated from EDGAR and paired with AI-powered summaries that highlight key points, such as changes in capital allocation, new debt offerings, productivity program charges or revisions to guidance. Users can quickly scan filings for material information while retaining access to the complete original documents for deeper analysis.
Colgate-Palmolive Chief Growth Officer John Hazlin reported equity compensation activity involving company common stock. On February 23, 2026, he acquired 12,803 shares through the vesting of performance-based restricted stock units granted under the incentive compensation plan. On the same date, 6,117 shares were disposed of at $97.10 per share to cover tax withholding related to that vesting. After these transactions, Hazlin directly owned 24,422 shares and indirectly held 5,452 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Legal Officer and Secretary Jennifer Daniels reported equity compensation activity in Common Stock. She acquired 25,742 shares through the vesting of previously granted performance-based restricted stock units that were earned under the company’s incentive compensation plan and settled in stock. To cover tax liabilities from this vesting, 12,351 shares were withheld at a price of $97.10 per share. After these transactions, she directly held 89,844 shares and indirectly held 1,837 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive EVP and Controller Malcolm Gregory reported equity award activity in company stock. He acquired 6,268 shares of Common Stock at a price of
On the same date, 2,260 shares of Common Stock were disposed of at
Colgate-Palmolive Chief Human Resources Officer Sally Massey reported stock-based compensation activity tied to performance awards. She acquired 16,805 shares of Common Stock at no cost from the vesting of previously granted performance-based restricted stock units earned under the company’s incentive plan. To cover tax obligations from this vesting, 8,206 shares were disposed of through a tax-withholding transaction at $97.10 per share, rather than an open-market sale. After these transactions, she directly owns 22,384 shares of Common Stock and indirectly holds 8,111 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive Chief Financial Officer Stanley J. Sutula III reported equity compensation activity involving the company’s common stock. He acquired 38,678 shares on February 23, 2026 through the vesting of previously granted performance-based restricted stock units earned under the incentive compensation plan.
On the same date, 19,746 shares were disposed of to cover tax withholding related to this vesting, rather than through an open-market sale. After these transactions, he held 74,320 shares directly and 328 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive COO Panagiotis Tsourapas received 25,742 shares of Common Stock on February 23, 2026 from vesting of performance-based restricted stock units earned under the company’s incentive plan. No cash changed hands for this award.
On the same date, 13,081 shares were withheld at $97.10 per share to cover related tax liabilities. After these transactions, he directly holds 21,629 shares, plus 4,568 shares through the issuer’s 401(k) plan trustee and 62,240 shares held by a trust.
Colgate-Palmolive Chairman, President & CEO Noel R. Wallace reported equity award activity in company stock. On February 23, 2026, he acquired 136,710 shares of Common Stock at $0.00 per share through vesting of previously granted performance-based restricted stock units earned under the incentive compensation plan. On the same date, 68,252 shares at $97.10 per share were withheld to cover tax obligations related to this vesting, a non-open-market disposition. Following these transactions, he directly owned 361,921 shares of Common Stock. He also had indirect holdings of 54,281 shares through the issuer's 401(k) plan trustee, 52,000 shares via a spouse trust, and 335 shares via another trust.
Colgate-Palmolive Company files its annual report describing a global consumer products business focused on Oral, Personal and Home Care and Pet Nutrition. In 2025, Oral Care, Personal Care and Home Care represented 44%, 17% and 16% of worldwide net sales, with Pet Nutrition at 23%.
The company highlights strong international exposure, with about two‑thirds of net sales from outside the United States and approximately 33,600 employees in over 100 countries as of December 31, 2025. It emphasizes brand strength in toothpaste, liquid hand soap, household cleaners and specialty pet food, supported by significant advertising and digital demand generation.
Key themes include heavy reliance on Walmart for about 11% of 2025 net sales, exposure to commodity and logistics cost volatility, and extensive discussion of geopolitical, cybersecurity, regulatory, climate and sustainability risks. The report also notes a new three‑year Strategic Growth and Productivity Program, a $5 billion share repurchase authorization approved in March 2025 and a non‑cash, after‑tax goodwill and intangible asset impairment charge of $794 million in the skin health business.
Tsourapas Panagiotis reported multiple insider transaction types in a Form 4 filing for CL. The filing lists transactions totaling 150,000 shares at a weighted average price of $85.99 per share. Following the reported transactions, holdings were 19,938 shares.
Colgate-Palmolive common stock holder plans Rule 144 sale of 15,000 shares of common stock through Merrill Lynch on the NYSE, with an aggregate market value of
The 15,000 shares were acquired on